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Highlights: 
 
 Malarial burden can be demonstrably reduced by interventions that inhibit the 
transmission of Plasmodium through the mosquito. These interventions are termed 
transmission-blocking interventions (TBIs).  
 Anti-parasitic forms of these interventions can be classified as transmission blocking 
drugs (TBDs), or transmission blocking vaccines (TBVs). 
 In terms of TBDs, there are currently three clinically approved anti-malarials that 
show robust transmission-blocking efficacy; primaquine, methylene blue and 
atovaquone, with additional compounds in clinical development and trials ongoing.  
 Although a wide range of proteins have been examined for TBV activity, there are 
only 5 immunogens that unquestionably demonstrate efficacy. Recent trials 
examining P230 and P25 and the development of a CMHI model to examine efficacy 
promise to give impetus to further development in the near future.  
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Abstract:  33 
 34 
Malaria remains a major global health challenge. Appropriate use of current anti-malarial 35 
tools has reduced the disease burden, but morbidity and mortality remain unacceptably 36 
high. It is widely accepted that to achieve long term control/eradication, it will be necessary 37 
to use interventions that inhibit the transmission of parasites to mosquitoes – these tools 38 
are termed Transmission Blocking Interventions (TBIs). This article aims to outline the 39 
rationale for the development of TBIs, with a focus on transmission-blocking drugs and 40 
transmission-blocking vaccines. We describe and summarise the current status of each of 41 
these intervention classes and attempt to identify future requirements in development, 42 
with a focus on the challenges of establishing each method within an integrated malarial 43 
control programme in the future.  44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
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1). Targeting malarial transmission – why? 65 
 66 
Malaria remains a major global health challenge with an estimated 216 million new cases 67 
and 445,000 deaths in 2016 [1]. Appropriate use of “historical”, currently existing anti-68 
malarial healthcare tools (e.g.; use of insecticide-treated bednets (ITN), artemisinin 69 
combination therapy (ACT) and increased access to higher quality healthcare) have 70 
substantially reduced the global burden of disease over the previous decade, however, 71 
progress has recently stalled and morbidity and mortality remain unacceptably high. It is 72 
obvious that new, innovative tools and approaches will be essential to achieve malaria 73 
control or elimination within the medium to long term. The causative agent of malaria, the 74 
protozoan parasite of the genus Plasmodium, is transmitted almost exclusively by Anopheles 75 
mosquitoes. Transmission of Plasmodium from humans to mosquitoes is entirely dependent 76 
on the presence of sexually committed, mature male and female gametocytes within the 77 
peripheral blood, which rapidly differentiate into flagellate male (micro) and sessile female 78 
(macro) gametes upon uptake by the mosquito within a blood meal. The subsequent 79 
process of parasitic fertilization is then initiated by gamete adhesion, followed by 80 
membrane, and nuclear fusion [2]. Following successful fertilization, the resulting parasitic 81 
zygotes develop into motile ookinetes, which migrate to and penetrate the midgut 82 
epithelium of the mosquito via the secretion of hydrolase (e.g. chitinase) and proteolytic 83 
(e.g. PPLP5) enzymes [3-5], enabling the progression of the lifecycle through development 84 
of oocysts and subsequent sporogony.  85 
 86 
It is widely accepted that to achieve eradication, it will be necessary to use interventions 87 
that inhibit the transmission of parasites from humans to mosquitoes - and vice versa [6]. 88 
Targeting malaria transmission is a logical concept. There are multiple advantageous 89 
characteristics of the fundamental biology of plasmodial transmission that render this 90 
process an attractive point of intervention. Firstly, the process of transmission from human 91 
to mosquito in the field typically results in the presence of <5 parasites (oocyst-stage) per 92 
mosquito [7] (although this figure is widely variable [8,9]). Conversely, in malaria infected 93 
humans, there are typically ~109 circulating parasites within the bloodstream, [10] resulting 94 
in an evident population bottleneck for the targeted killing of parasites within this stage of 95 
the lifecycle.  Allied to this, sexually mature parasites are extracellular for ~24 hours in the 96 
4 
 
mosquito (compared to ~30 seconds in humans during merozoite invasion [11]), resulting in 97 
a larger window of opportunity to target the parasite for immune/pharmacological 98 
destruction. Finally, the genes expressed in the sexual stages of the parasite life cycle are 99 
genetically invariant compared to blood/liver-stage genes [12-14], with the comparative 100 
reduction in polymorphism resulting in a conceptual reduction in resistance, and 101 
subsequent pathogen escape.  102 
 103 
Allied to these key biological concepts, clear evidence exists that targeting malarial 104 
transmission is effective in a global context. Modelling studies clearly demonstrate the 105 
potential utility of targeting transmission, from the early dynamical models of Ross and 106 
Macdonald [15], followed by the development of cyclic feeding models [16,17], simulation 107 
of both vector transmission dynamics and within-human parasite dynamics [18,19]. 108 
Specialist models to predict impact on transmission alone also show impact across multiple 109 
vector ecologies and behaviours [20]. The benefits of targeting transmission and the 110 
mosquito vector were elegantly demonstrated by Bhatt et al., [21], in a study linking a large 111 
database of African field studies with detailed reconstructions of changing intervention 112 
coverage to quantify the attributable effect of individual malaria control efforts. The authors 113 
clearly demonstrate that broad interventions targeting the vector/ transmission - i.e. ITNs, 114 
and indoor residual spraying (IRS) are by far the most important interventions in Africa, 115 
responsible for an estimated 68% and 13% of the reduction in P. falciparum prevalence 116 
(PfPR2-10) since 2000-2015 (Figure 1). This is a clear indication of the potential clinical global 117 
value of targeting the transmission of Plasmodium through the mosquito host. 118 
 119 
Examination, development and assessment of interventions specifically targeting malarial 120 
transmission is timely. The current stall in efforts to control malaria [1], reliance on a 121 
relatively narrow toolkit of clinical interventions, increasing risk of resistance to anti-122 
malarial drugs and insecticides [22,23], and the potential of transmission blocking 123 
interventions to complement (or synergise with) other anti-malarial control methods 124 
currently available, or in the later stages of a development pipeline (e.g. the pre-125 
erythrocytic vaccine RTS,S) [10] renders this approach particularly opportune. A potential 126 
manner of interrupting parasitic transmission directly is by targeting Plasmodium using 127 
transmission-blocking interventions (TBIs). These can be broadly classified as transmission 128 
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blocking drugs (TBDs), or transmission blocking vaccines (TBVs), against the parasitic sexual 129 
stages (e.g. gametocytes/gametes/ookinetes). Here, we describe and summarise the 130 
current status of each of these intervention classes and attempt to identify future 131 
requirements and trends in their development, with a focus on the potential implications 132 
and challenges of establishing each method within an integrated malarial control 133 
programme in the future.  134 
 135 
2). Anti-malarial transmission blocking drugs (TBDs) – present and future? 136 
 137 
Mature, mosquito-infectious gametocytes maintain an arrested state of cellular 138 
development in peripheral circulation and show divergent transcriptomes and proteomes 139 
from asexual stages [24-26]. As a consequence of this, they are insensitive to most 140 
schizonticidal antimalarials [27-28]. To identify drugs and small molecules with the potential 141 
to block transmission, numerous high throughput transmission screening assays have been 142 
developed [28-34]. The updated Medicines for Malaria Venture target candidate profile for 143 
a transmission-blocking drug (TCP-5) states that it should ideally “have activity against all 144 
five differentiated forms of gametocytes (stages I–V), plus inhibition of oocyst or sporozoite 145 
formation in the mosquito vector” [35]. There are three clinically approved antimalarials 146 
that show well-supported transmission-blocking efficacy (Figure 2): primaquine (PQ), 147 
methylene blue (MB) and atovaquone (ATQ). 148 
 149 
PQ is an 8-aminoquinoline used predominantly in the cure of P.vivax relapsing infections by 150 
eliminating the dormant liver hynozoite stage of the parasite. Its effectiveness additionally 151 
against transmission stages has been known for over half a century, targeting mature 152 
gametocytes by an unknown mechanism that manifests in accelerated gametocyte 153 
clearance and cumulative impaired development of subsequent mosquito stages [36]. 154 
However. PQ causes haemolytic anaemia in G6PD deficient individuals – a mutation 155 
widespread across Sub-Saharan Africa, thus limiting its use [37]. Nevertheless, low doses of 156 
PQ are now recommended by the WHO for transmission-blocking 157 
(www.who.int/malaria/publications/atoz/who_htm_gmp_2015.1.pdf), with positive field 158 
trials in both safety and efficacy [38,39]. MB appears to perturb the redox balance within 159 
the parasite and is effective against asexuals, gametocytes and mosquito stages [27,40], 160 
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with conflicting evidence against liver stages of the life cycle [27,41]. Clinical trials have 161 
found three days of 15mg/kg MB is similarly efficacious as a single low dose (0.25mg/kg) of 162 
PQ at preventing transmission to the mosquito [39]. ATQ targets the parasite cytochrome 163 
bc1 and interrupts mitochondrial function [42]. In combination with proguanil (Malarone®), 164 
it is primarily used for chemoprophylaxis to prevent the development of liver stage 165 
parasites. However, ATQ has potent activity against ookinete and oocyst formation in the 166 
mosquito when carried across in the bloodmeal [43]. Intriguingly, sera from ATQ-treated 167 
volunteers (n=3) has been found to block transmission for over 35 days after treatment [44]. 168 
Furthermore, although ATQ drug resistance in asexual parasites can arise within the patient 169 
rather rapidly, these mutations render the parasite sterile for transmission and so resistance 170 
is not heritable [45]. Although no large clinical trials have studied ATQ as a transmission-171 
blocking agent, with the expiry of the patent for Malarone® in 2013, it is tempting to 172 
speculate that a similar atovaquone-combination therapy could provide an effective and 173 
long-lasting “chemical vaccine” to prevent transmission in a mass drug administration 174 
setting. 175 
 176 
Looking to the future, antimalarials with transmission-blocking activity have been prioritised 177 
with several in various stages of clinical development. Cipargamin® (KAE609/NITD609) 178 
developed by Novartis has recently completed phase IIa clinical trials [46]. Cipargamin 179 
inhibits PfATP4, a putative Na+ efflux pump, causing an intracellular osmotic imbalance 180 
within the cell [47]. Interestingly this causes the parasitized cell to swell and become rigid 181 
and likely contributes to accelerated clearance by the spleen in vivo [48]. It also has in vitro 182 
activity against early and late gametocytes, and oocyst development in the mosquito albeit 183 
all at relatively high doses compared to asexual activity [49]. How this translates into 184 
transmission-blocking efficacy in vivo remains to be determined. Similarly, MMV048 [50] 185 
and SJ733 [51], also both PfATP4 inhibitors are entering phase IIa and first in human trials 186 
respectively. KAF156, also developed by Novartis, is a rapid-acting antimalarial that is 187 
effective gametocytes in vitro and mosquito transmission both in vitro and in vivo in a P. 188 
berghei rodent model of infection [52]. The molecular target of KAF156 is unknown 189 
although resistance has been generated though mutations in PfCARL, PfACT and PfUGT 190 
[52,53]. Phase IIb trials in combination with lumefantrine are ongoing, and currently there is 191 
no published clinical data on its transmission-blocking activity [54]. 192 
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 193 
To date transmission-blocking activity has been regarded as giving added value to 194 
schizonticides. As a consequence, dosing regimens are designed with asexual treatment 195 
rather than transmission-blocking in mind. In vitro data of the most advanced transmission-196 
blocking molecules shows that they require drug concentrations about an order of 197 
magnitude higher to be efficacious. This has several implications for clinical trials. Firstly, 198 
due to sub-effective dosing, there is the danger that expectations of efficacy will not be met, 199 
resulting in a drain in the scientific/political will to continue this approach. More worryingly, 200 
if resistance mechanisms in asexual parasites also translate to resistance in gametocytes 201 
which are already less sensitive to the particular drug, there likely will be preferential 202 
transmission of resistance alleles. An alternative approach increasingly being considered is 203 
the concept of a transmission-specific drug. This class of antimalarial would specifically 204 
target biological pathways specific to gametocytes and/or mosquito stages with no activity 205 
against asexual stages. When administered in combination with a schizonticidal therapy to 206 
cure the patient and clear residual asexuals (i.e. the source of new gametocytes), 207 
transmission would be completely abrogated, with the added benefits of minimising the 208 
chance of resistance selection to the transmission-blocking component (smaller target 209 
population = decreased probability of resistance) and protecting the “shelf-life” of the 210 
partner schizonticide(s) by preventing the propagation of any generated resistance alleles 211 
through transmission. 212 
 213 
3). Anti-malarial transmission blocking vaccines (TBVs) – present and future? 214 
 215 
The induction of transmission-blocking immunity as a potential tool in malarial control was 216 
first demonstrated in the avian malaria parasite P. gallinacium [55,56]. Since then, the 217 
feasibility of an anti-malarial TBV has been demonstrated in multiple species, with a wide 218 
range of target antigens, expression systems and delivery methods assessed and examined.  219 
 220 
Parasite-derived molecules of interest for transmission blocking purposes can be assigned to 221 
one of two broad categories; 1). Proteins expressed in gametocytes and gametes, immunity 222 
against which will be naturally boosted by infection; and 2). Proteins expressed solely in the 223 
gamete, zygote and ookinete stages of the mosquito vector, which are therefore never 224 
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expressed within the human host. A perceived advantage to this is that these antigens are 225 
never exposed to immune pressure in a vertebrate population and are therefore less likely 226 
to exhibit extensive sequence variation [57] Conversely, the vast majority of gametocytes 227 
are destined to die within the human host, and therefore all gametocyte antigens, 228 
irrespective of cellular localisation, will be presented to the host immune system. Such 229 
responses will “naturally boost” vaccine-induced immunity targeted to some gametocyte 230 
antigens, but vaccines targeting ookinete-specific immunogens would not have this benefit 231 
[58]. It is still unclear which of these contradictory concepts is more advantageous in 232 
practical terms when deploying a TBV. A third class of TBV immunogen has been 233 
characterised relatively recently – mosquito-derived antigens that can be targeting by 234 
vaccination to inhibit penetration of the midgut epithelium (e.g. APN1, FREP1 [59,60]. 235 
Although undoubtedly a promising approach, this text is limited to descriptions of parasite-236 
derived TBVs only. Table 1 shows a range of parasitic molecules (both pre-and post-237 
fertilisation) that are considered to be potential candidate TBV antigens. Although a wide 238 
range of parasite proteins have been examined for TBV activity over the previous decades, 239 
there are still only 5 immunogens that unquestionably and reproducibly demonstrate 240 
transmission blocking immunity and efficacy. These antigens are; 1). P230, 2). P48/45, 3). 241 
HAP2, 4). P25, 5). P28. (Table 1).  242 
 243 
P48/45, Pfs230 and HAP2 are all pre-fertilisation targets, expressed during gametocyte 244 
development, and all have a functional role in parasitic fertilisation. P48/45 and P230 are 245 
synthesised in the gametocyte, are co-expressed, and are essential for the adhesion of male 246 
(micro)-gametes to female (macro)-gametes. Antibodies against both of these antigens 247 
expressed in a range of heterologous systems have shown significant transmission-blocking 248 
activity in the Standard Membrane Feeding Assay (SMFA) and the Direct Membrane Feeding 249 
Assay (DMFA) (outlined in [61,62]). Clinical development of both of these immunogens is 250 
relatively advanced, with the development of the Pfs48/45-derived immunogen R0-6C [63] 251 
encompassing the optimisation of upstream immunogen production, downstream 252 
purification, and optimisation of immunogenicity currently underway [64,65]. Studies using 253 
Pfs230-derived antigen as a TBV are particularly advanced at present, with Pfs230D1 254 
showing high levels of functional activity in non-human primates and in US-based clinical 255 
trials [66,67]. Studies of Pfs230 immunisation followed by Direct Skin Feeding (DSF) in Mali 256 
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have demonstrated immunogenicity and activity in the field, with acceptable toleration and 257 
reproducible antibody responses following vaccination [67,68]. It should be noted that anti-258 
P230 TBV activity has been demonstrated to be entirely complement-dependent [69]. 259 
Studies of both of these candidate TBVs are at a particularly exciting phase, with impressive 260 
recent progress in terms of antigenic production and the generation of initial proof of 261 
concept data in humans. HAP2 is a male-specific class II fusogen first identified in plants and 262 
has been shown to be essential for post-adhesion membrane fusion of the male and female 263 
gametocyte during fertilization [70]. Polyclonal antibodies against DII and DIII of P. berghei 264 
and P. falciparum HAP2 expressed in E. coli and wheat-germ cell free system have also 265 
exhibited high levels of transmission-blocking activity in pre-clinical studies [71,72], whereas 266 
antibodies against the short “fusion loop” of the protein have also resulted in transmission 267 
blocking efficacy in the lab (SMFA) and the field (DMFA) [2]. Combination of these findings 268 
to facilitate the clinical examination of HAP2 as a candidate TBV are ongoing.  269 
 270 
The most extensively studied post-fertilisation candidates are P25 and P28, two GPI-271 
anchored, EGF-domain containing, paralogous proteins with mutually redundant functions 272 
expressed on the surface of zygotes and ookinetes [73]. P25 is the most extensively studied 273 
TBV candidate, with a wide range of studies examining efficacy of P25-derived TBV 274 
immunogens previously reported. Although clear efficacy has been demonstrated in the lab 275 
with anti-P25 TBVs in many studies [74-47], and in the field, with serum derived from 276 
vaccination with anti-P25 TBVs followed by DMFA [76-78], direct demonstration of efficacy 277 
in humans following immunisation has been challenging. The first Phase Ia trials of 278 
recombinant Pfs25 in formulation with potent adjuvants (e.g. Pfs25-Montanide ISA21 [94]) 279 
lead to unacceptable levels of reactogenicity. More recently, a range of studies exploring 280 
different conjugates of Pfs25 (e.g. Pfs25-EPA, Pfs25-GPI), use of different adjuvants (e.g. 281 
AS01), use of transgenic parasites as expression systems, viral-vectored Pfs25 (e.g. ChAd63-282 
Pfs25 and Pfs25-IMX313) have significantly advanced knowledge of this antigen [74,76,79]. 283 
Clinical of Pfs25-EPA in in clinical trials in the US and Phase Ib trials in Mali have 284 
demonstrated induction of functional antibody, but directly comparative data seems to 285 
show a lower efficacy with Pfs25-derived vaccine when compared to the use of Pfs230 as an 286 
immunogen [66-68].  287 
 288 
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The above five antigens are logically considered to be “priority” immunogens for vaccine 289 
development, although concerted efforts to broaden the repertoire of available antigens 290 
are ongoing. Surprisingly, discovery of the majority of these priority immunogens stems 291 
largely from historic studies where often crudely fractionated parasites were used to 292 
immunise mice to produce monoclonal antibodies, which were in turn validated by Western 293 
blot and laborious functional assays [80-83]. It is important to consider that these efforts are 294 
likely to identify only the most immunogenic of the natural antigens present in the whole-295 
cell preparations used, and do therefore not preclude the discovery of new candidates for 296 
antigenic components of TBVs. Efforts to identify novel antigens using more advanced use 297 
of concerted ‘omics’ screens have only relatively recently started to yield the discovery of 298 
new TBV antigen candidates [84-87], although none have so far demonstrated reproducible 299 
efficacy or sufficient volume of data to a level where they are currently considered “priority” 300 
TBV candidates. This is unsurprising, considering the (well described) long period of time it 301 
takes to identify and validate malaria vaccine candidates, our gaps in knowledge about the 302 
effector arms of long-lasting anti-parasitic immunity, and the complex nature of the vaccine 303 
development pipeline, with no definitive targets for mode of action, assay threshold, or 304 
required efficacy in the lab or the field [88]. Information regarding some of these 305 
biologically fascinating “current non-priority” candidates is outlined in Table 1. Hopefully, 306 
these studies will yield a wider range of new and improved vaccine candidates to bolster the 307 
development pipeline in the near future. This is likely to be essential for the future utility of 308 
TBVs as a practical anti-malarial intervention.  309 
 310 
4). Concluding remarks – what needs to be better?   311 
 312 
Although undoubted progress has been made relatively recently in the efforts to control 313 
malaria, the disease remains a major issue in endemic areas, resulting in substantial impacts 314 
on morbidity/mortality and significant economic repercussions. The development of TBIs to 315 
contribute towards the drive to control/eliminate malaria has greatly accelerated relatively 316 
recently, to the extent that such interventions are already utilized as part of a clinical 317 
treatment pathway (in the case of PQ), or are tools that are likely to be integrated into 318 
clinical use in the near future. However, a large range of outstanding issues still need to be 319 
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resolved to optimise the use of these potentially powerful interventions. Some of these 320 
issues are discussed below (and see Outstanding Questions)..  321 
 322 
In terms of TBDs, although current field trials on an individual patient scale show efficacy, 323 
there is still a disappointing lack of trials showing the impact of TBD at the population level 324 
to reduce new cases of malaria [89]. It is known that asymptomatic submicroscopic 325 
gametocyte carriers contribute significantly to the infectious reservoir of malaria and so just 326 
treating symptomatic patients that present to the clinic is insufficient to impact 327 
transmission. “Test and treat” mass drug administration campaigns may be more effective; 328 
however, the current limiting factor is the lack of affordable and sufficiently rapid diagnostic 329 
tests for gametocytemia that can be used at the point of care to identify submicroscopic 330 
infections. Clearing this hurdle will facilitate the treatment coverage required for 331 
transmission-blocking, but overcoming the regulatory and psychological barriers of treating 332 
what to all purposes appear healthy individuals with a drug that helps the “next” patient 333 
need still to be addressed. 334 
 335 
The practical development and use of a TBV within the field also requires a range of 336 
fundamental additional research. As discussed previously, there are only 5 “proven”/priority 337 
antigens for use as TBV components. It is exceptionally unlikely that this range of targets is 338 
sufficient to drive a long-term, robust development pipeline, thus the discovery of 339 
additional molecules/epitopes that can initiate a transmission-blocking response is essential 340 
and timely. Supplementary to this, the TBV development pipeline remains broadly opaque 341 
and undemocratic, with unclear go/no-go criteria for onward development from 342 
fundamental lab-based studies, and no clearly defined efficacy requirements for TBVs. This 343 
is likely due to the well-acknowledged disconnect between lab- and field-based assays to 344 
assess transmission-blockade [88,90]. Due to practical, concerted effort, this situation has 345 
improved in recent years, with in depth discussion and development of multiple 346 
assays/models to evaluate the biological efficacy of TBIs [90,91]. The development of a 347 
controlled human malaria infection (CHMI) model to facilitate the evaluation of TBIs within 348 
a controlled context [92,93] is exceptionally promising and has the promise to fill a critical 349 
gap within the development pipeline. The ability of TBVs to complement other, non-350 
transmission-based interventions should also be examined carefully. Further down the 351 
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pipeline, it is essential for investigators and regulators to agree on future regulatory 352 
requirements and follow the most efficient acceptable clinical development plan. The 353 
design of Phase I, II, and large-scale population-based Phase III trials evaluating efficacy 354 
against infection and clinical endpoints promises to be challenging, but not insurmountable, 355 
and is likely to be vital to demonstrate the impact of a TBV and subsequently to achieve 356 
licensure.  357 
 358 
Despite these ongoing issues, it is vital to acknowledge the considerable advances that have 359 
been made in recent years in terms of reducing global malaria burden and the development 360 
and assessment of multiple TBIs. Increased momentum and continued support for the 361 
development of these logical interventions promises to generate a wider range of powerful 362 
tools to continue our current progress, both in isolation, and in combination with a range of 363 
other anti-malarial interventions.  364 
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Figure Legends: 731 
 732 
Figure 1. Changing endemicity and effect of interventions 2000–2015. Predicted time series 733 
of population-weighted mean PfPR2–10 across endemic Africa. The red line shows the actual 734 
prediction and the black line a ‘counterfactual’ prediction in a scenario without coverage by 735 
ITNs, ACTs or IRS. The coloured regions indicate the relative contribution of each 736 
intervention in reducing PfPR2–10 throughout the period. Adapted from Bhatt et al., (2015), 737 
Nature; 526(7572):207-211. 738 
 739 
Figure 2. A summary of the transmission-blocking effects of clinically approved 740 
transmission-blocking drugs on the transmission stages of the Plasmodium life cycle. 741 
 742 
Table 1. Parasitic molecules (both pre-and post-fertilisation) that are under consideration 743 
as potential candidate TBV antigens. Antigens are either classed as “priority”, or “under 744 
examination and consideration”. Please note that “studies of interest” are not intended to 745 
be an exhaustive list of relevant studies, but sensible starting points for further in-depth 746 
reading. 747 
 748 
 749 
 750 
 751 
 752 
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 753 
 754 
 755 
 756 
 757 
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"Priority antigens" 
Pre-fertilisation Post-fertilisation 
Antigen Studies of interest Antigen Studies of interest 
P48/45 
Outchkourov et al. 2008; van Djik et al. 2001/2008; Theisen et al. 
2014; Singh et al. 2015  P25 
Kaslow et al. 1994, Radtke et al. 2017; Talaat et al. 2016; 
Scally et al., 2017 
P230 
Williamson et al. 1995; Tachibana et al.2012; Farrance et al. 2011; 
MacDonald et al., 2016 P28 Quian et al. 2009; Kim et al. 2011 
HAP2 
Blagborough & Sinden 2009; Miura et al. 2013; Angrisano et al. 
2017     
        
"Antigens under examination and consideration" 
Pre-fertilisation Post-fertilisation 
Antigen Studies of interest Antigen Studies of interest 
Pfg27 Lobo Konings & Kumar 1994; Lobo et al. 1999; Ploton et al. 1995 CelTOS Kariu et al. 2006;  
PfMR5  Eksi & Williamson 2002 Chitinase 
Shahabuddin 1995; Langer et al. 2002; Li et al. 2005; Takeo 
et al. 2009 
Pfs16 Lobo Konings & Kumar 1994; Moelans et al. 1995 Enolase Ghosh et al. 2011 
Pfs2400/Pf11-1 Feng et al. 1993 PfGAP50 Beiss et al. 2015; Simon et al. 2013 
Plasmepsin 4 Li , Patra et al. 2010  PSOP12 Sala et al. 2015 
PfCCP/LAP proteins Scholz et al. 2008; Carter et al.2008; Saeed et al. 2010  SOAP Dessens et al. 2003 
GEST  Talman et al., 2011 Plasmepsin 7 Li et al. 2016 
Pfs47  
van Schaijk et al. 2006; Tachibana et al. 2015; Molina-Cruz et al., 
2015 Plasmepsin 10 Li et al. 2016 
PSOP12 Sala et al., 2015 CTRP  Trottein 1995; Ramakrishnan et al. 2011 
    MAOP/PPLP3 Kadota et al. 2004; Kaiser et al. 2004, Ecker 2007 
   PPLP5  Ecker 2007; Kadota 2004 
   PSOP25 Zheng et al., 2016 
   PbPH Xou et al., 2016 
   PSOP7 Zheng et al., 2016 
    PSOP26 Zheng et al., 2016 
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Outstanding Questions: 
 
 When considering the use of transmission-blocking drugs, its it viable to, and can we 
effectively implement “test and treat” mass drug administration campaigns? 
Asymptomatic submicroscopic gametocyte carriers contribute significantly to the 
infectious reservoir of malaria and only treating symptomatic patients that present 
to the clinic is insufficient. Mass drug administration campaigns maybe effective; but 
confounding factors to this approach are costs, and lack of rapid diagnostic tests for 
gametocytemia that can be used at the point of care. Even if these technical issues 
are overcome to facilitate the treatment coverages required for effective 
transmission-blocking, is it possible to overcome the regulatory and psychological 
issues of treating what to all purposes appear “healthy” individuals with a drug that 
helps the “next” patient?  
 Is it viable to utilize transmission-specific drugs, with no activity against asexual 
stages, within a clinical pathway in the future?  
 There is a potentially insufficient number of TBV immunogens currently available, 
with are only 5 “proven”/priority antigens for use as TBV components. How do we 
effectively boost this number of available targets in the future, balancing the desire 
to increase the number of molecules within a robust development pipeline, whilst 
maintaining (or increasing) current immunogenicity and efficacy? 
 How do we accelerate and democratize the TBV development pipeline? What 
desirable go/no-go criteria do we set for the triage and development of TBVs, and 
how do we reconcile lab and field-based assays? What do Phase III trials look like, 
and what licencing pathway is the most practical to follow? 
 What level of TBV coverage is acceptable to maintain effectiveness in the field, and 
how does this relate to “standard” measures of efficacy? 
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